Contact
searchSearch
HMP Global
Login

Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma
Specialty Channel
Marco Ruella, MD
Videos
Ten-Year Outcomes With Tisagenlecleucel Demonstrate Durable Remissions in B-Cell Lymphoma
07/01/2026
Marco Ruella, MD
Marco Ruella, MD, discusses 10-year follow-up data showing that tisagenlecleucel produced durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, supporting the long-term curative...
Marco Ruella, MD, discusses 10-year follow-up data showing that tisagenlecleucel produced durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, supporting the long-term curative...
Marco Ruella, MD, discusses...
07/01/2026
Oncology
Christopher Fox, MD, PhD
Videos
Epcoritamab Produces Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
06/23/2026
Christopher Fox, MD, PhD
Christopher Fox, MD, PhD, discusses results from the phase 3 EPCORE DLBCL-1 trial showing that epcoritamab significantly improved progression-free survival, complete response rates, duration of response, and time to next treatment compared...
Christopher Fox, MD, PhD, discusses results from the phase 3 EPCORE DLBCL-1 trial showing that epcoritamab significantly improved progression-free survival, complete response rates, duration of response, and time to next treatment compared...
Christopher Fox, MD, PhD,...
06/23/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Emerges as Potential New Standard in High-Risk Diffuse Large B-Cell Lymphoma
06/15/2026
Stephanie Holland
Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from the phase 3...
06/15/2026
Oncology
News
Addition of Polatuzumab to R-ICE Falls Short in Second-Line Large B-Cell Lymphoma
06/11/2026
Stephanie Holland
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
Results from a phase 3 study...
06/11/2026
Oncology
News
R-CHOP-Like Therapy Retreatment Yields Durable Responses in Late-Relapsing Diffuse Large B-Cell Lymphoma
04/17/2026
Emily Estrada
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with...
04/17/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
Chan Cheah, MBBS
Conference Coverage
Epcoritamab Plus R-Mini-CHOP Demonstrates Durable Efficacy and Manageable Safety for Elderly Patients With DLBCL: 2-Year Results From EPCORE NHL-2
12/23/2025
Chan Cheah, MBBS
Epcoritamab plus R-mini-CHOP achieved high and durable response rates with manageable toxicity among elderly, treatment-naïve patients with DLBCL, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Epcoritamab plus R-mini-CHOP achieved high and durable response rates with manageable toxicity among elderly, treatment-naïve patients with DLBCL, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Epcoritamab plus R-mini-CHOP...
12/23/2025
Oncology
Krish Patel, MD
Conference Coverage
Quality Improvement Project Identifies Knowledge Gaps and Barriers to Bispecific Antibody Use in Community Oncology Practices
12/17/2025
Krish Patel, MD
At the 2025 ASH Annual Meeting & Exposition, Krish Patel, MD, shared insights into the development of a quality improvement initiative aimed to identify barriers of bispecific antibody use in community oncology practices.
At the 2025 ASH Annual Meeting & Exposition, Krish Patel, MD, shared insights into the development of a quality improvement initiative aimed to identify barriers of bispecific antibody use in community oncology practices.
At the 2025 ASH Annual Meeting &...
12/17/2025
Oncology
Conference Coverage
Real-World ctDNA Monitoring Shows MRD Clearance Predicts Relapse Risk and Survival Outcomes for DLBCL: HOVON-902 Analysis
12/11/2025
Emily Estrada
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring...
12/11/2025
Oncology
Conference Coverage
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
Conference Coverage
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L DLBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology

News

News
Tafasitamab Plus Lenalidomide and R-CHOP Emerges as Potential New Standard in High-Risk Diffuse Large B-Cell Lymphoma
06/15/2026
Stephanie Holland
Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from the phase 3...
06/15/2026
Oncology
News
Addition of Polatuzumab to R-ICE Falls Short in Second-Line Large B-Cell Lymphoma
06/11/2026
Stephanie Holland
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
Results from a phase 3 study...
06/11/2026
Oncology
News
R-CHOP-Like Therapy Retreatment Yields Durable Responses in Late-Relapsing Diffuse Large B-Cell Lymphoma
04/17/2026
Emily Estrada
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with...
04/17/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
Chan Cheah, MBBS
Conference Coverage
Epcoritamab Plus R-Mini-CHOP Demonstrates Durable Efficacy and Manageable Safety for Elderly Patients With DLBCL: 2-Year Results From EPCORE NHL-2
12/23/2025
Chan Cheah, MBBS
Epcoritamab plus R-mini-CHOP achieved high and durable response rates with manageable toxicity among elderly, treatment-naïve patients with DLBCL, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Epcoritamab plus R-mini-CHOP achieved high and durable response rates with manageable toxicity among elderly, treatment-naïve patients with DLBCL, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Epcoritamab plus R-mini-CHOP...
12/23/2025
Oncology
Krish Patel, MD
Conference Coverage
Quality Improvement Project Identifies Knowledge Gaps and Barriers to Bispecific Antibody Use in Community Oncology Practices
12/17/2025
Krish Patel, MD
At the 2025 ASH Annual Meeting & Exposition, Krish Patel, MD, shared insights into the development of a quality improvement initiative aimed to identify barriers of bispecific antibody use in community oncology practices.
At the 2025 ASH Annual Meeting & Exposition, Krish Patel, MD, shared insights into the development of a quality improvement initiative aimed to identify barriers of bispecific antibody use in community oncology practices.
At the 2025 ASH Annual Meeting &...
12/17/2025
Oncology
Conference Coverage
Real-World ctDNA Monitoring Shows MRD Clearance Predicts Relapse Risk and Survival Outcomes for DLBCL: HOVON-902 Analysis
12/11/2025
Emily Estrada
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring...
12/11/2025
Oncology
Conference Coverage
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
Conference Coverage
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L DLBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology
Conference Coverage
Zanubrutinib Plus R-CHOP Therapy Shows Promising Efficacy, Acceptable Safety Among Patients With DLBCL Harboring Specific Gene Subtypes
12/02/2025
Emily Estrada
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy...
12/02/2025
Oncology

Interactive Features

Quiz
Polatuzumab-Based Therapy for R/R DLBCL
12/01/2025
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab...
12/01/2025
Oncology
Quiz
Polatuzumab-Based Regimens for R/R DLBCL
10/28/2025
True or False: Compared to patients with R/R DLBCL treated with traditional salvage therapies, patients treated with polatuzumab vedotin and zanubrutinib combined with either rituximab or obinutuzumab demonstrated inferior clinical outcomes...
True or False: Compared to patients with R/R DLBCL treated with traditional salvage therapies, patients treated with polatuzumab vedotin and zanubrutinib combined with either rituximab or obinutuzumab demonstrated inferior clinical outcomes...
True or False: Compared to...
10/28/2025
Oncology
Quiz
Epcoritamab Plus R-ICE for R/R DLBCL
09/26/2025
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
True or False: According to...
09/26/2025
Oncology
Quiz
Efficacy and Safety of Tazemetostat for R/R DLBCL and FL
08/25/2025
True or False: Based on results from a meta-analysis evaluating the safety and efficacy of tazemetostat among patients with R/R FL or DLBCL, the EZH2 inhibitor demonstrated promise as a viable treatment option, demonstrating meaningful...
True or False: Based on results from a meta-analysis evaluating the safety and efficacy of tazemetostat among patients with R/R FL or DLBCL, the EZH2 inhibitor demonstrated promise as a viable treatment option, demonstrating meaningful...
True or False: Based on results...
08/25/2025
Oncology
Quiz
Autologous Hematopoietic Cell Transplantation or CAR-T Therapy for Patients With Relapsed LBCL
09/30/2024
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to...
09/30/2024
Oncology
Quiz
Induction Therapy With High-Dose Chemo, Autologous HSCT in Patients With PCNSL
04/11/2024
04/11/2024
Oncology
Quiz
Blinatumomab After ASCT as a Treatment Option Among Patients With Relapsed DLBCL
02/27/2024
02/27/2024
Oncology
Quiz
Treating DLBCL With Tafasitamab Plus R-CHOP, With or Without Lenalidomide
12/15/2023
True or False: According to findings from the phase 1b First-MIND study, tafasitamab plus the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen with or without the addition of lenalidomide demonstrated...
True or False: According to findings from the phase 1b First-MIND study, tafasitamab plus the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen with or without the addition of lenalidomide demonstrated...
True or False: According to...
12/15/2023
Oncology
Quiz
Acalabrutinib Plus Danvatirsen for R/R DLBCL
12/05/2023
What were the key findings of the phase 1 PRISM trial, which investigated the use of BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen among patients with R/R DLBCL?
What were the key findings of the phase 1 PRISM trial, which investigated the use of BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen among patients with R/R DLBCL?
What were the key findings of...
12/05/2023
Oncology
Quiz
Standard vs 4-Cycle Regimen of R-CHOP for Non-Bulky, Low-Risk DLBCL
11/07/2023
According to findings from a phase 3 trial, how did a 4-cycle regimen of R-CHOP compare to the standard regimen in treating patients with non-bulky, low-risk DLBCL?
According to findings from a phase 3 trial, how did a 4-cycle regimen of R-CHOP compare to the standard regimen in treating patients with non-bulky, low-risk DLBCL?
According to findings from a...
11/07/2023
Oncology

Recent News

News
Tafasitamab Plus Lenalidomide and R-CHOP Emerges as Potential New Standard in High-Risk Diffuse Large B-Cell Lymphoma
06/15/2026
Stephanie Holland
Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from the phase 3...
06/15/2026
Oncology
News
Addition of Polatuzumab to R-ICE Falls Short in Second-Line Large B-Cell Lymphoma
06/11/2026
Stephanie Holland
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
Results from a phase 3 study...
06/11/2026
Oncology
News
R-CHOP-Like Therapy Retreatment Yields Durable Responses in Late-Relapsing Diffuse Large B-Cell Lymphoma
04/17/2026
Emily Estrada
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with...
04/17/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
Conference Coverage
Real-World ctDNA Monitoring Shows MRD Clearance Predicts Relapse Risk and Survival Outcomes for DLBCL: HOVON-902 Analysis
12/11/2025
Emily Estrada
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring...
12/11/2025
Oncology
Conference Coverage
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
Conference Coverage
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L DLBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology
Conference Coverage
Zanubrutinib Plus R-CHOP Therapy Shows Promising Efficacy, Acceptable Safety Among Patients With DLBCL Harboring Specific Gene Subtypes
12/02/2025
Emily Estrada
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy...
12/02/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Shows Efficacy and Safety Among Elderly, Chemotherapy-Ineligible Patients With DLBCL: MorningSun Trial
12/02/2025
Emily Estrada
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at...
12/02/2025
Oncology
News
Nivolumab Plus R-CHOP Shows Promising Efficacy and Tolerability for Newly Diagnosed DLBCL
12/01/2025
Emily Estrada
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a...
12/01/2025
Oncology
News
Durvalumab Plus Anlotinib Maintenance Improves PFS in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Maintenance therapy with durvalumab plus anlotinib improved progression-free survival compared with durvalumab alone in patients with extensive-stage small cell lung cancer following first-line chemoimmunotherapy, according to results from...
Maintenance therapy with durvalumab plus anlotinib improved progression-free survival compared with durvalumab alone in patients with extensive-stage small cell lung cancer following first-line chemoimmunotherapy, according to results from...
Maintenance therapy with...
07/02/2026
Oncology
News
Serplulimab Plus Chemotherapy Shows Sustained Survival Benefit in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Updated findings from the ASTRUM-005 trial showed that adding serplulimab to carboplatin and etoposide continued to improve long-term survival in patients with previously untreated extensive-stage small cell lung cancer.
Updated findings from the ASTRUM-005 trial showed that adding serplulimab to carboplatin and etoposide continued to improve long-term survival in patients with previously untreated extensive-stage small cell lung cancer.
Updated findings from the...
07/02/2026
Oncology
News
Real-World Study Confirms Survival Benefit of First-Line Chemoimmunotherapy in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Real-world data from a large retrospective cohort study demonstrated that first-line chemoimmunotherapy significantly improved survival in patients with extensive-stage small cell lung cancer.
Real-world data from a large retrospective cohort study demonstrated that first-line chemoimmunotherapy significantly improved survival in patients with extensive-stage small cell lung cancer.
Real-world data from a large...
07/02/2026
Oncology
FDA Approval
FDA Approves BESREMi Pen, Expanding Self-Administration Options for Patients With Polycythemia Vera
07/01/2026
Emily Estrada
The FDA has approved the BESREMi Pen, a prefilled ropeginterferon alfa-2b-njft delivery device, for adults with polycythemia vera, providing a new option designed to simplify self-administration of chronic interferon therapy.
The FDA has approved the BESREMi Pen, a prefilled ropeginterferon alfa-2b-njft delivery device, for adults with polycythemia vera, providing a new option designed to simplify self-administration of chronic interferon therapy.
The FDA has approved the BESREMi...
07/01/2026
Oncology
News
MRI-Guided Adaptive Radiotherapy Enables Margin Reduction in Adult Patients With Glioblastoma
06/30/2026
Emily Estrada
Results from the phase 2 UNITED trial demonstrated that MRI-guided adaptive radiotherapy with reduced treatment margins was associated with a low rate of marginal failure in adult patients with glioblastoma.
Results from the phase 2 UNITED trial demonstrated that MRI-guided adaptive radiotherapy with reduced treatment margins was associated with a low rate of marginal failure in adult patients with glioblastoma.
Results from the phase 2 UNITED...
06/30/2026
Oncology
News
WT1 Peptide Vaccine Demonstrates Immune Activity in Pediatric High-Grade Gliomas
06/30/2026
Emily Estrada
Results from a phase 1/2 study demonstrated that a Wilms' tumor gene 1 (WT1) peptide vaccine is well tolerated and elicited immune responses associated with improved survival among pediatric patients with high-grade gliomas.
Results from a phase 1/2 study demonstrated that a Wilms' tumor gene 1 (WT1) peptide vaccine is well tolerated and elicited immune responses associated with improved survival among pediatric patients with high-grade gliomas.
Results from a phase 1/2 study...
06/30/2026
Oncology
News
Venetoclax-Based Conditioning Regimen Prior to Allo-HSCT for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
06/30/2026
Emily Estrada
Results from a phase 2 trial demonstrated that incorporating venetoclax into a fludarabine and melphalan conditioning regimen before allogeneic hematopoietic stem cell transplantation showed encouraging clinical promise in older patients with...
Results from a phase 2 trial demonstrated that incorporating venetoclax into a fludarabine and melphalan conditioning regimen before allogeneic hematopoietic stem cell transplantation showed encouraging clinical promise in older patients with...
Results from a phase 2 trial...
06/30/2026
Oncology
News
Navitoclax Plus Venetoclax and Decitabine Shows Early Activity in High-Risk Myeloid Malignancies
06/30/2026
Emily Estrada
Results from a phase 1 study demonstrated that the addition of navitoclax to venetoclax plus decitabine was safe and showed encouraging preliminary activity among patients with high-risk myeloid malignancies.
Results from a phase 1 study demonstrated that the addition of navitoclax to venetoclax plus decitabine was safe and showed encouraging preliminary activity among patients with high-risk myeloid malignancies.
Results from a phase 1 study...
06/30/2026
Oncology
News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use